Moderna stock price could surge another 45% on COVID-19 vaccine - Business Insider

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 23 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 13%
  • Publisher: 51%

ایران اخبار اخبار

ایران آخرین اخبار,ایران سرفصلها

Moderna is poised to surge another 45% in the next year, COVID-19 vaccine could generate more than $5 billion in annual sales, Jefferies says

is set to surge higher even after its epic 220% rally so far this year, according to Jefferies.

The bullish rating hinges on Moderna's COVID-19 vaccine working and resulting in large government supply contracts, Jefferies equity analyst Michael Yee wrote in a Monday note. In the first full year of sales of its potential vaccine, Jefferies' model shows it could bring in $2 billion worldwide if roughly 50 million people get the vaccine at $50. This could grow to a peak of $5 billion between 2025 and 2026, according to the note.

 

از نظر شما متشکرم. نظر شما پس از بررسی منتشر خواهد شد.

English press release of Dr. Zelenko new study. Please share. Treat early and live. Combo works.

این خبر را خلاصه کرده ایم تا بتوانید سریع آن را بخوانید. اگر به خبر علاقه مند هستید، می توانید متن کامل را اینجا بخوانید. ادامه مطلب:

 /  🏆 729. in İR

ایران آخرین اخبار, ایران سرفصلها

Similar News:همچنین می توانید اخبار مشابهی را که از منابع خبری دیگر جمع آوری کرده ایم، بخوانید.

ICU head in Bergamo, Italy, says COVID-19 causing 'chronic damage' - Business InsiderBusiness Insider is a fast-growing business site with deep financial, media, tech, and other industry verticals. Launched in 2007, the site is now the largest business news site on the web.
منبع: BusinessInsider - 🏆 729. / 51 ادامه مطلب »